NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025
1. NewAmsterdam will present pivotal Alzheimer’s data on July 30, 2025. 2. Presentation highlights obicetrapib effects on Alzheimer's in cardiovascular patients. 3. Conference call with key speakers streamlines upcoming data overview. 4. Obicetrapib shows significant LDL-lowering effects, aiding cardiovascular disease patients. 5. Commercial rights granted to Menarini Group for European obicetrapib distribution.